																CIC)N	IS	FO	RN	
SUSPECT A	ADVERSE R	FAC	TION REPO	RT																	
3031 201 2	ADVENSE IV	LAC	IION KLI O	111						_			_				_	_	_	_	
			I DEA	CTIO	N INFOF	NAATION															
1. PATIENT INITIALS	1a. COUNTRY	2. D	ATE OF BIRTH	2a. AGE	_	3a. WEIGHT		-6 RE	ACTIO	10 N	NSET	г	8-1	2 (CHE	ECK	AL	L			
(first, last)	OSTA RICA	Day	Month Year	40		Unk	Day	_	Month	ı	Υe	ear 25		1	APF	PROF	PRI	IATE	E TO	ON ON	
PRIVACY			RIVACY	Years	Female				FEE	5	20	25] F	PATIE	ENT DIE	ED				
7 + 13 DESCRIBE REACTION(S Other Serious Criteria: M			ata)										Σ	a "	NVO	LVED (OR				
Event Verbatim [PREFERR	RED TERMI (Related	i	D		0	I laka d	Repo	orter	С	omi	pany		_	Ė	HOSE	ONGE	SATI	ON			
Event Verbatim [PREFERRED TERM] (Related symptoms if any separated by commas)			Product		Serious	Listed No	Caus	ality	, c	aus	ality		L	_ (INVOLVED PERSISTENT OR SIGNIFICANT DISABILITY OR						
KNEE PAIN [Arthralgia] INFLAMMATION OF THE STOMACH [Gastritis]		OSIMERTINIB OSIMERTINIB		No	No				Related Related			INCAPACITY									
	TOMACH PROBLEMS [Gastrointestinal		OSIMERTINIB		No	No	Related		R	Related			LIFE THREATENING				NG	3			
disorder] RASHES ON THE CHEST AND CHEEKS [Rash]		OSIMERTINIB		No	Yes	Related I		R	Related			Г			GENITA	٩L					
ACNE [Acne]			OSIMERTINIB		No	Yes	Rela	Related Related				ANOMALY OTHER									
					(Conti	nued on Add	litiona	ıl Inf	format	tion	Paç	ge)	Σ	<u> </u>	JINE	:K					
			II. SUSPEC	CT DR	UG(S) IN	NFORMA	TIO	N													
14. SUSPECT DRUG(S) (include generic name) #1) OSIMERTINIB (OSIMERTINIB) Tablet 20. DID REACTION ABATE AFTER STOPPING DRUG?																					
						. ROUTE(S) OF ADMINISTRATION 1) Oral use								□ `	YES	N	0	×	۱A		
17. INDICATION(s) FOR USE #1) LUNG CANCER (Lung neoplasm malignant) 21. DID REACTION REAPPEAR AFTER REINTRODUCTION?																					
, ,						. THERAPY DURATION 1) Unknown						YES NO NA									
		III.	CONCOMI	TANT	DRUG(S	S) AND H	IIST	OF	RY												
22. CONCOMITANT DRUG(S)	AND DATES OF ADMI	INISTRATI	ON (exclude those us	sed to treat	reaction)																
23. OTHER RELEVANT HISTOR From/To Dates	RY. (e.g. diagnostics,		regnancy with last mo e of History / Notes	onth of peri	od, etc.) Description																
Unknown to Ongoing		Ind	dication		Lung car	ncer (Lung	neop	olas	m ma	aligi	nan	ıt)									
		_	IV. MANUI	FACTI	JRER IN	FORMA	TIOI	V				_		_		_		_			
24a. NAME AND ADDRESS OF MANUFACTURER 26. REMARKS																					
AstraZeneca Serban Ghiorghiu						World Wide #: CR-AstraZeneca-2024A184539 Study ID: PSP-23269															
1 Medimmune Way Gaithersburg, Maryland 20878 UNITED STATES					,	Case References: CR-AstraZeneca-2024-270966															
Phone: +1 301-398-000	00																				
24b. MFR CONTROL NO.					25b. NA	ME AND ADDR	ESS O	F RF	PORTE	ER.							_				
2024A184539					25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.																
24c. DATE RECEIVED 24d. REPORT SOURCE					NAME	NAME AND ADDRESS WITHHELD.															
BY MANUFACTURER STUDY LITERATURE					NAME	NAME AND ADDRESS WITHHELD.															
29-MAY-2025 HEALTH PROFESSIONAL OTHER:					NAME	NAME AND ADDRESS WITHHELD.															
DATE OF THIS REPORT 04-JUN-2025	25a. REPORT	TYPE	N FOLLOWER	4	NAME	AND ADD	RESS	s w													
	INITIAL		FOLLOWUP:	1	1							ued	on A	Addi	ition	al Info	orm	natio	n Pa	ige)	

ADDITIONAL INFORMATION

7+13. DESCRIBE REACTION(S) continued

Event Verbatim [PREFERRED TERM] (Related symptoms if any separated by commas)	Product	Serious	Listed	Reporter Causality	Company Causality
"I have a bacterial infection" [Bacterial infection]	OSIMERTINIB	Yes	No	Not Applicable	Not Related
"Intense pain on my right side" [Pain]	OSIMERTINIB	Yes	No	Not Applicable	Not Related
Fever [Pyrexia]	OSIMERTINIB	Yes	No	Not Applicable	Not Related
Sensitive skin [Sensitive skin]	OSIMERTINIB	Yes	No	Not Applicable	Related
Constant urination [Pollakiuria]	OSIMERTINIB	Yes	No	Not Applicable	Not Related
Constipation [Constipation]	OSIMERTINIB	Yes	No	Not Applicable	Related
Kidney stones [Nephrolithiasis]	OSIMERTINIB	Yes	No	Not Applicable	Not Related
nails fell [Nail avulsion]	OSIMERTINIB	No	No	Related	Related
dark spots on my face [Pigmentation disorder]	OSIMERTINIB	No	No	Related	Related
they're itching me a lot [Pruritus]	OSIMERTINIB	No	Yes	Related	Related

Case Description: A solicited report has been received from a consumer in Patient Support Program concerning a female adult patient born in 1985 (age 40 years).

No medical history was reported. No concomitant products were reported.

On 06-Jan-2024, the patient started treatment with Osimertinib (osimertinib) 80 milligram qd, Oral use, for lung cancer.

During 15-Feb-25, the patient experienced kidney stones (preferred term: Nephrolithiasis). On 30-Mar-25, the patient experienced i have a bacterial infection (preferred term: Bacterial infection), constipation (preferred term: Constipation), constant urination (preferred term: Pollakiuria), sensitive skin (preferred term: Sensitive skin), fever (preferred term: Pyrexia) and intense pain on my right side (preferred term: Pain). On an unknown date, the patient experienced stomach problems (preferred term: Gastrointestinal disorder), dark spots on my face (preferred term: Pigmentation disorder), nails fell (preferred term: Nail avulsion), they're itching me a lot (preferred term: Pruritus), inflammation of the stomach (preferred term: Gastritis), knee pain (preferred term: Arthralgia), acne (preferred term: Acne) and rashes on the chest and cheeks (preferred term: Rash).

The dose of Osimertinib was not changed.

The outcome of the events of kidney stones was unknown. At the time of reporting, the event i have a bacterial infection, intense pain on my right side, acne, constant urination, constipation, dark spots on my face, fever, inflammation of the stomach, knee pain, nails fell, rashes on the chest and cheeks, sensitive skin, stomach problems and they're itching me a lot was ongoing.

The reporter assessed the events of i have a bacterial infection, intense pain on my right side, fever, sensitive skin, constant urination and constipation as serious due to hospitalized criterion.

The reporter assessed the event of kidney stones as serious due to medically significant criterion.

The reporter assessed the events of acne, inflammation of the stomach, knee pain, nails fell, rashes on the chest and cheeks and stomach problems as non-serious.

The company physician assessed the events of dark spots on my face and they're itching me a lot as non-serious.

The reporter did not assess causality for i have a bacterial infection, intense pain on my right side, constant urination, constipation, fever, kidney stones and sensitive skin.

The reporter considered that there was a reasonable possibility of a causal relationship between Osimertinib and the following events: acne, dark spots on my face, inflammation of the stomach, knee pain, nails fell, rashes on the chest and cheeks, stomach problems and they're itching me a lot.

The company physician did not consider that there was a reasonable possibility of a causal relationship between Osimertinib and the following events: i have a bacterial infection, intense pain on my right side, constant urination, fever and kidney stones. The company physician considered that there was a reasonable possibility of a causal relationship between Osimertinib and the following events: acne, constipation, dark spots on my face, inflammation of the stomach, knee pain, nails fell, rashes on the chest and cheeks, sensitive skin, stomach problems and they're itching me a lot.

Summary of follow-up information received by AstraZeneca/MedImmune on 2-Apr-2025 from Other Health Professional via solicited source: product start date updated, narrative updated.

Summary of follow-up information received by AstraZeneca/MedImmune on 29-May-2025 from Consumer via Patient Support Program source: Primary reporter consumer was added. New non-serious events Nails fell and Dark spots on my face and They're itching me a lot were added. Narrative updated.

Company Clinical Comment: Constipation and sensitive skin are not listed in the company core data sheet for Osimertinib. Underlying lung cancer could be confounding to the events. Advanced age could be contributing factor for the event. Due to limited information on the circumstances leading to events, clinical course, concomitant conditions, risk factors, relevant medical history, concomitant medication, status of underlying malignancy, detailed diagnostic and etiologic workup, the evaluation did not find the evidence to exclude a reasonable possibility of a causal relationship between the events and suspect drug.

ADDITIONAL INFORMATION

25b. Name And Address of Reporters continued NAME AND ADDRESS WITHHELD.

NAME AND ADDRESS WITHHELD.